<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>274829</rcn>
  <id>101248226</id>
  <acronym>FIBROLEAD</acronym>
  <teaser><![CDATA[Inflammatory bowel disease (IBD), which comprises Crohn's disease (CD) and ulcerative colitis (UC), is a growing global health challenge affecting over 6.8 million people. Characterized by chronic inflammation leading to intestinal fibrosis, IBD significantly reduces quality...]]></teaser>
  <objective><![CDATA[Inflammatory bowel disease (IBD), which comprises Crohn's disease (CD) and ulcerative colitis (UC), is a growing global health challenge affecting over 6.8 million people. Characterized by chronic inflammation leading to intestinal fibrosis, IBD significantly reduces quality of life and increases the risk of severe complications, including colon cancer. Current treatments primarily target inflammation, and fail to address the persistent activation of inflammatory fibroblast phenotypes and the resulting fibrosis, contributing to frequent relapses and a heightened risk of disease progression.
To address this gap, FIBROLEAD introduces a pioneering approach by targeting fibroblasts, key mediators of chronic inflammation and fibrosis in IBD. Our recent research identified VM-313 to effectively disrupt pathogenic fibroblast activation. We now have evidence that this compound has a strong potential in mitigating both inflammation and fibrosis in vitro, ex vivo and in a mouse model of lung fibrosis. Additionally, it exhibits a favourable safety/toxicity profile and drug-like properties that are equal or superior to currently available anti-fibrotic drugs. These findings position VM-313 as a promising candidate for expanding and improving therapeutic strategies for IBD and other fibrotic diseases.
This PoC project aims to develop VM-313 as an advanced lead and validate its clinical and commercial potential. Our approach includes assessing its in vivo safety and efficacy in animal models of IBD and determining its mode of action via target identification and validation studies. In parallel, we will develop a comprehensive business case, engage with key stakeholders, and conduct a commercial assessment to evaluate market entry potential. By leveraging our unique targeting strategy and the advantages of a non-invasive oral therapy, VM-313 has the potential to transform IBD treatment, delivering significant benefits to patients.]]></objective>
  <title>A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2025-08-01</startDate>
  <endDate>2027-01-31</endDate>
  <ecSignatureDate>2025-07-30</ecSignatureDate>
  <duration>18</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101248226</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-08-04 12:52:04</sourceUpdateDate>
  <contentCreationDate readOnly="true">2025-08-05 10:23:09</contentCreationDate>
  <contentUpdateDate>2025-08-04 12:52:04</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-11-13 11:18:05</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <rcn>460267</rcn>
        <id>460267-targeting-fibroblasts-as-a-treatment-for-inflammatory-bowel-disease</id>
        <title>Targeting fibroblasts as a treatment for inflammatory bowel disease</title>
        <contentUpdateDate>2025-11-13 11:18:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode readOnly="true">/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode readOnly="true">/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode readOnly="true">/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>57153</rcn>
        <title>ERC-2025-POC</title>
        <identifier>ERC-2025-POC</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>57153</rcn>
        <title>ERC-2025-POC</title>
        <identifier>ERC-2025-POC</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="150000" terminated="false" sme="true" netEcContribution="150000" totalCost="0" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1993896</rcn>
        <id>873220288</id>
        <vatNumber>EL802724190</vatNumber>
        <legalName>INOLYSIS MONOPROSOPI IDIOTIKI KEFALAIOUCHIKI ETAIREIA</legalName>
        <address>
          <street>TRAPEZOUNTOS 17</street>
          <city>MELISSIA ATHENS</city>
          <postalCode>151 27</postalCode>
          <country>EL</country>
          <geolocation>37.9226935,23.750136050000002</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Βόρειος Τομέας Αθηνών</name>
              <rcn>1465368</rcn>
              <nutsCode>EL301</nutsCode>
              <parents>
                <region>
                  <name>Aττική</name>
                  <rcn>1464908</rcn>
                  <nutsCode>EL30</nutsCode>
                  <parents>
                    <region>
                      <name>Αττική </name>
                      <rcn>1464907</rcn>
                      <nutsCode>EL3</nutsCode>
                      <parents>
                        <region>
                          <name>Greece</name>
                          <rcn>240552488</rcn>
                          <nutsCode>EL</nutsCode>
                          <euCode>EL</euCode>
                          <isoCode>EL</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Greece</name>
              <rcn>240552488</rcn>
              <nutsCode>EL</nutsCode>
              <euCode>EL</euCode>
              <isoCode>EL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>709388</rcn>
        <id>HORIZON_ERC-2025-POC</id>
        <code>ERC-2025-POC</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode readOnly="true">/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
